Received: from DBAPR02MB6247.eurprd02.prod.outlook.com (2603:10a6:10:198::19) by VI1PR02MB5024.eurprd02.prod.outlook.com with HTTPS; Thu, 27 Aug 2026 13:17:27 +0000 Received: from GV2PR02MB11921.eurprd02.prod.outlook.com (2603:10a6:150:351::5) by DBAPR02MB6247.eurprd02.prod.outlook.com (2603:10a6:10:198::19) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.21.360.8; Thu, 27 Aug 2026 13:17:26 +0000 Received: from GV2PR02MB11921.eurprd02.prod.outlook.com ([fe80::9f24:8c81:10e8:7104]) by GV2PR02MB11921.eurprd02.prod.outlook.com ([fe80::9f24:8c81:10e8:7104%4]) with mapi id 15.21.0360.008; Thu, 27 Aug 2026 13:17:26 +0000 From: "Kristi Sarap - RA" To: Subject: Ravimiameti vastus Date: Thu, 27 Aug 2026 16:17:26 +0300 Message-ID: MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="----=_NextPart_000_026F_01DD4047.895BE6A0" X-Mailer: Microsoft Outlook 16.0 Thread-Index: AQJYuBGxbWNwobhwznIA/29voOlxrQ== Authentication-Results: dkim=none (message not signed) header.d=none;dmarc=none action=none header.from=ravimiamet.ee; X-MS-Has-Attach: X-MS-TNEF-Correlator: x-ms-exchange-messagesentrepresentingtype: 1 x-ms-traffictypediagnostic: GV2PR02MB11921:EE_|DBAPR02MB6247:EE_|VI1PR02MB5024:EE_ X-MS-Office365-Filtering-Correlation-Id: 2a71a42b-cc88-4bb8-d6cd-08df043d89c6 X-MS-Exchange-AtpMessageProperties: SA X-MS-Exchange-Transport-CrossTenantHeadersStamped: DBAPR02MB6247 X-CodeTwoProcessed: true X-MS-Exchange-Organization-ExpirationStartTime: 27 Aug 2026 13:17:26.6245 (UTC) X-MS-Exchange-Organization-ExpirationStartTimeReason: OriginalSubmit X-MS-Exchange-Organization-ExpirationInterval: 1:00:00:00.0000000 X-MS-Exchange-Organization-ExpirationIntervalReason: OriginalSubmit X-MS-Exchange-Organization-Network-Message-Id: 2a71a42b-cc88-4bb8-d6cd-08df043d89c6 X-MS-Exchange-Organization-MessageDirectionality: Originating X-MS-PublicTrafficType: Email X-MS-Exchange-Organization-AuthSource: GV2PR02MB11921.eurprd02.prod.outlook.com X-MS-Exchange-Organization-AuthAs: Internal X-MS-Exchange-Organization-SCL: 1 X-Microsoft-Antispam: BCL:0;ARA:13230040|366016|23010399003|39142699007|31052699007|10067099003|56012099006|11063799006|8096899003|55112099003|18002099003|41050700001; X-Forefront-Antispam-Report: CIP:255.255.255.255;CTRY:;LANG:et;SCL:1;SRV:;IPV:NLI;SFV:NSPM;H:GV2PR02MB11921.eurprd02.prod.outlook.com;PTR:;CAT:NONE;SFS:(13230040)(366016)(23010399003)(39142699007)(31052699007)(10067099003)(56012099006)(11063799006)(8096899003)(55112099003)(18002099003)(41050700001);DIR:INT; X-MS-Exchange-CrossTenant-OriginalArrivalTime: 27 Aug 2026 13:17:26.0352 (UTC) X-MS-Exchange-CrossTenant-Network-Message-Id: 2a71a42b-cc88-4bb8-d6cd-08df043d89c6 X-MS-Exchange-CrossTenant-Id: 8fe098d2-428d-4bd4-9803-7195fe96f0e2 X-MS-Exchange-CrossTenant-AuthSource: GV2PR02MB11921.eurprd02.prod.outlook.com X-MS-Exchange-CrossTenant-AuthAs: Internal X-MS-Exchange-CrossTenant-FromEntityHeader: Hosted X-MS-Exchange-Transport-EndToEndLatency: 00:00:01.6222108 X-MS-Exchange-Processed-By-BccFoldering: 15.21.0360.006 X-MS-Exchange-ExternalInOutlookResult: NotEnabled X-Microsoft-Antispam-Mailbox-Delivery: ucf:0;jmr:0;auth:0;dest:I;ENG:(910005)(944506478)(944626604)(920097)(425001)(930201)(20251009189)(140003); X-Microsoft-Antispam-Message-Info: 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 Content-Language: et acceptlanguage: et-EE, en-US x-ms-exchange-organization-originalclientipaddress: 45.156.32.33 x-ms-exchange-organization-originalserveripaddress: 2603:10a6:150:351::5 X-OlkEid: 00000000B02CA1B0966F474A8EB1ED1092032AA5070034AD76187591974DBF6C4F76951C873A01000200000000000C9DC03918ACEF4596C0CB2D860A15F300000000142300002FE07E661F9105498D534F0C21600E07 X-MS-Exchange-Organization-ModifySensitivityLabel: 00000000-0000-0000-0000-000000000000;defa4170-0d19-0005-0004-bc88714345d2 x-codetwo-clientsignature-inserted: true X-MS-Exchange-Organization-AuthMechanism: 04 X-MS-Exchange-Organization-Recipient-P2-Type: Bcc X-MS-Exchange-CrossTenant-MailboxType: HOSTED X-MS-Exchange-CrossTenant-UserPrincipalName: l01zx7um3PE2H5BXRonw2AMx4OR04zuvI1zznKsd7E8EyhM4pHzv2jl3t46CRU1RGTWk44Ep8WeRuaABo2XONWjOIsGSGvq9gkkx5sokec9oW/QK4kEkbQ9XK6UA8KHu msip_labels: MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Enabled=True;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_SiteId=8fe098d2-428d-4bd4-9803-7195fe96f0e2;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_SetDate=2026-08-27T13:17:25.642Z;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Name=All Employees (unrestricted);MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_ContentBits=1;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Method=Standard; This is a multipart message in MIME format. ------=_NextPart_000_026F_01DD4047.895BE6A0 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: 8bit Tere, Merilin! Reklaamiseaduse kohaselt on tervishoiuteenuse reklaam keelatud. Paragrahvis on sätestatud erisused ning loetelu tegevustest, mida tervishoiuteenuse reklaamiks ei loeta ning on seega lubatud, mh on lubatud doonorite leidmiseks vajalike abinõude rakendamine. Nende nõuete täitmise üle teeb järelevalvet Terviseamet. Saame Ravimiameti poolt lisada, et kõik doonorid peavad andma kirjaliku nõusoleku enne sugurakkude loovutamist. Selleks, et nõusolek oleks kehtiv, peab eelnevalt olema antud doonorile kirjalikult või kirjalikku taasesitamist võimaldavas vormis teavet: 1) rakkude eemaldamise eesmärgi ja iseloomu kohta; 2) rakkude eemaldamise tagajärgede ja ohtude kohta; 3) enne rakkude eemaldamist tehtud uuringute ja nende tulemuste kohta; 4) doonori isikuandmete registreerimise ja kaitse kohta; 5) annetatud rakkude eesmärgi ja võimalike kasutegurite kohta; 6) doonori elu ja tervise kaitseks rakendatavate ohutusabinõude kohta. Kliinik peab doonorile andma teavet, millised tagajärjed ja ohud rakkude annetamisega kaasnevad. Ravimiamet kontrollib inspektsioonides pisteliselt ka doonorite nõusolekuid. Kristi Sarap kommunikatsiooninõunik Ravimiamet Ravimiamet 7374140 www.ravimiamet.ee Selles e-kirjas sisalduv teave (kaasa arvatud manused) on mõeldud ametialaseks kasutamiseks ning seda võivad kasutada vaid e-kirja adressaadid. E-kirjas sisalduvat teavet ei tohi ilma saatja selgelt väljendatud loata edasi saata ega mis tahes viisil kolmandatele isikutele avaldada. Juhul, kui Te olete saanud käesoleva e-kirja eksituse tõttu, teavitage sellest koheselt saatjat ning kustutage e-kiri. This e-mail and any attachments transmitted may contain confidential and privileged information. If you are not the intended recipient, please notify the sender immediately by returning the e-mail and permanently deleting what you have received. Any dissemination or use of this information by a third person without permission is prohibited and may be illegal. ------=_NextPart_000_026F_01DD4047.895BE6A0 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable
Tere, Merilin!

Reklaamiseaduse kohaselt on tervishoiuteenuse reklaam keelatud. = Paragrahvis on s=C3=A4testatud erisused ning loetelu tegevustest, mida = tervishoiuteenuse reklaamiks ei loeta ning on seega lubatud, mh on = lubatud doonorite leidmiseks vajalike abin=C3=B5ude = rakendamine. Nende n=C3=B5uete t=C3=A4itmise =C3=BCle teeb j=C3=A4relevalvet = Terviseamet.
Saame Ravimiameti poolt lisada, et k=C3=B5ik doonorid peavad andma = kirjaliku n=C3=B5usoleku enne sugurakkude loovutamist. Selleks, et = n=C3=B5usolek oleks kehtiv, peab eelnevalt olema antud doonorile = kirjalikult v=C3=B5i kirjalikku taasesitamist v=C3=B5imaldavas vormis = teavet:
1) rakkude eemaldamise eesm=C3=A4rgi ja iseloomu kohta;
2) rakkude eemaldamise tagaj=C3=A4rgede ja ohtude kohta;
3) enne rakkude eemaldamist tehtud uuringute ja nende tulemuste = kohta;
4) doonori isikuandmete registreerimise ja kaitse kohta;
5) annetatud rakkude eesm=C3=A4rgi ja v=C3=B5imalike kasutegurite = kohta;
6) doonori elu ja tervise kaitseks rakendatavate ohutusabin=C3=B5ude = kohta.
Kliinik peab doonorile andma teavet, millised tagaj=C3=A4rjed ja ohud = rakkude annetamisega kaasnevad. Ravimiamet kontrollib inspektsioonides = pisteliselt ka doonorite n=C3=B5usolekuid. 


Kristi = Sarap
kommunikatsioonin=C3=B5unik
Ravimiamet

Ravimiamet
7374140
www.ravimiamet.ee

Selles e-kirjas = sisalduv teave (kaasa arvatud manused) on m=C3=B5eldud ametialaseks = kasutamiseks ning seda v=C3=B5ivad kasutada vaid e-kirja adressaadid. = E-kirjas sisalduvat teavet ei tohi ilma saatja selgelt v=C3=A4ljendatud loata edasi saata ega mis tahes viisil kolmandatele isikutele avaldada. = Juhul, kui Te olete saanud k=C3=A4esoleva e-kirja eksituse t=C3=B5ttu, = teavitage sellest koheselt saatjat ning kustutage e-kiri.
This e-mail and any = attachments transmitted may contain confidential and privileged = information. If you are not the intended recipient, please notify the = sender immediately by returning the e-mail and permanently deleting what you have received. Any dissemination or use of this = information by a third person without permission is prohibited and may = be illegal.

------=_NextPart_000_026F_01DD4047.895BE6A0--